Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

PlastiPure, ReliaBrand partner to produce EA-Free plastic consumer products

PlastiPure, a safer-plastics technology company, has announced a partnership with ReliaBrand to license infant feeding, sports bottle, food packaging, and medical products free of harmful chemicals that cause estrogenic activity (EA). Chemicals with EA have been strongly linked to adverse health effects such as birth defects, reproductive cancers, and behavioral and learning disorders. The widely known chemicals BPA and phthalates are only a few of thousands of chemicals suspected to have EA.

11 Oct 2010

FDA issues CRL for AZ-004 NDA application

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato loxapine), submitted as Adusuve Staccato (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

ImmunoGen enter collaboration agreement with Novartis to develop targeted anticancer therapeutics

ImmunoGen, Inc. announced today that it has entered into a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis.

11 Oct 2010

HHS awards Sanofi Pasteur 3-year, $56.94M egg supply contract for pandemic vaccine preparedness

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, has been awarded a three-year contract for $56.94 million by the U.S. Department of Health and Human Services (HHS) to maintain flocks to enable manufacturing pandemic influenza vaccine at full capacity on a year-round basis.

11 Oct 2010

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Cincinnati Children's Hospital Medical Center has been named one of five national Centers of Excellence for Molecular Hematology to find new gene and cell therapies for inherited diseases affecting blood cells.

8 Oct 2010

Emergent BioSolutions and TLV form new joint venture to develop flu vaccines

Emergent BioSolutions Inc., a U.S.-based developer and manufacturer of vaccines and antibody therapies, today launched its Singapore operations.

8 Oct 2010

U.N. Secretary-General urges funding for GAVI during replenishment meeting

U.N. Secretary-General Ban Ki-moon has urged more funding for the GAVI Alliance to help achieve its childhood vaccine targets and the related Millennium Development Goals (MDGs), TopNews reports.

8 Oct 2010

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three contracts could reach $68 million, depending on the successful completion of defined project milestones.

8 Oct 2010

International scientific conference explores new approaches to prevent infectious diseases

Swine flu, cancer, bioterrorism and the latest trends in countermeasures to combat these life-threatening diseases and infections are among the topics to be discussed at the upcoming New Cells for New Vaccines V: Global Perspectives international scientific conference, on October 11-13 in Wilmington, Delaware, at the Hotel du Pont.

8 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.

8 Oct 2010

FDA files complaint for permanent injunction against Brooklyn Juice Company

At the request of the U.S. Food and Drug Administration, the U.S. Department of Justice today filed a complaint for permanent injunction against a Brooklyn juice company to prevent it from processing and distributing juice products.

8 Oct 2010

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Advanced Medical Isotope Corporation, a company engaged in the production and distribution of medical isotopes, is delighted to announce the execution of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.

7 Oct 2010

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).

7 Oct 2010

AngioDynamics reports 3% increase in net sales for fiscal 2011 first quarter

AngioDynamics, a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today reported financial results for the fiscal 2011 first quarter ended August 31, 2010 that were in line with the preliminary results reported on September 7, 2010.

7 Oct 2010

GeoVax receives US Patent for pGA series of plasmids

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has been issued via an exclusive license from Emory University, a US Patent for its "DNA expression vectors and methods of use. Issued on September 14, 2010, the patent claims cover novel vectors and novel HIV vaccine inserts.

7 Oct 2010

DSM project on carbon dioxide footprint reduction receives European Outsourcing Awards

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, is pleased to announce that their submission for the European Outsourcing Awards, organized by Via Media UK Ltd, entitled Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate was an award recipient at the 6th October ceremony held in Paris, France.

7 Oct 2010

Soy germ-based nutritional supplement helps to manage menopausal symptoms

A new women-s health, whole soy germ-based nutritional supplement containing Natural S-equol reduced the frequency of moderate to severe hot flashes and reduced muscle and joint pain in the first study of its kind among postmenopausal U.S. women, according to peer-reviewed data presented as a poster presentation at the North American Menopause Society (NAMS) Annual Meeting.

7 Oct 2010

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

The company Synthetic Genomics Inc. (SGI) and the not-for-profit research organization, the J. Craig Venter Institute (JCVI) today announced the formation of a new company, Synthetic Genomics Vaccines Inc. (SGVI).

7 Oct 2010

Manufacturing News and Research

Further Reading

PlastiPure, ReliaBrand partner to produce EA-Free plastic consumer products

FDA issues CRL for AZ-004 NDA application

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

ImmunoGen enter collaboration agreement with Novartis to develop targeted anticancer therapeutics

HHS awards Sanofi Pasteur 3-year, $56.94M egg supply contract for pandemic vaccine preparedness

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Emergent BioSolutions and TLV form new joint venture to develop flu vaccines

U.N. Secretary-General urges funding for GAVI during replenishment meeting

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

International scientific conference explores new approaches to prevent infectious diseases

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

FDA files complaint for permanent injunction against Brooklyn Juice Company

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

AngioDynamics reports 3% increase in net sales for fiscal 2011 first quarter

GeoVax receives US Patent for pGA series of plasmids

DSM project on carbon dioxide footprint reduction receives European Outsourcing Awards

Soy germ-based nutritional supplement helps to manage menopausal symptoms

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News